Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Saturated Fatty Acid Combined with Lipopolysaccharide Stimulates a Strong Inflammatory Response in Hepatocytes in vivo and in vitro.

Li Y, Lu Z, Ru JH, Lopes-Virella MF, Lyons TJ, Huang Y.

Am J Physiol Endocrinol Metab. 2018 Jul 10. doi: 10.1152/ajpendo.00015.2018. [Epub ahead of print]

PMID:
29989851
2.

LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages.

Jin J, Lu Z, Li Y, Ru JH, Lopes-Virella MF, Huang Y.

J Leukoc Biol. 2018 Jun 8. doi: 10.1002/JLB.3A0517-188RRR. [Epub ahead of print]

PMID:
29882996
3.

Modified LDL immune complexes and cardiovascular disease.

Lopes-Virella MF, Virella G.

Curr Med Chem. 2018 May 23. doi: 10.2174/0929867325666180524114429. [Epub ahead of print]

PMID:
29792135
4.

Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D.

Basu A, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Schade DS, Wood J, Alaupovic P, Lyons TJ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

J Lipid Res. 2018 May;59(5):872-883. doi: 10.1194/jlr.P080143. Epub 2018 Mar 25.

PMID:
29576550
5.

Late adulthood mortality among African-American and white American people with Type 1 diabetes according to age at diabetes diagnosis.

Conway BN, Lopes-Virella MF, Blot WJ.

Diabet Med. 2018 Jun;35(6):729-736. doi: 10.1111/dme.13617. Epub 2018 Mar 30.

PMID:
29532512
6.

Docosahexaenoic acid antagonizes the boosting effect of palmitic acid on LPS inflammatory signaling by inhibiting gene transcription and ceramide synthesis.

Jin J, Lu Z, Li Y, Cowart LA, Lopes-Virella MF, Huang Y.

PLoS One. 2018 Feb 23;13(2):e0193343. doi: 10.1371/journal.pone.0193343. eCollection 2018.

7.

Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort.

Hunt KJ, Jaffa MA, Garrett SM, Luttrell DK, Lipson KE, Lopes-Virella MF, Luttrell LM, Jaffa AA; VADT Investigators.

Diabetes Care. 2018 Apr;41(4):840-846. doi: 10.2337/dc17-2083. Epub 2018 Jan 30.

PMID:
29382658
8.

Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes.

Baker NL, Hunt KJ, Stevens DR, Jarai G, Rosen GD, Klein RL, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Diabetes Care. 2018 Jan;41(1):128-135. doi: 10.2337/dc17-0867. Epub 2017 Nov 8.

PMID:
29118060
9.

Cooperative stimulation of atherogenesis by lipopolysaccharide and palmitic acid-rich high fat diet in low-density lipoprotein receptor-deficient mice.

Lu Z, Li Y, Brinson CW, Lopes-Virella MF, Huang Y.

Atherosclerosis. 2017 Oct;265:231-241. doi: 10.1016/j.atherosclerosis.2017.09.008. Epub 2017 Sep 9.

PMID:
28934649
10.

Relationship between risk factor control and vascular events in the SAMMPRIS trial.

Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, Janis LS, Lane B, Montgomery J, Chimowitz MI.

Neurology. 2017 Jan 24;88(4):379-385. doi: 10.1212/WNL.0000000000003534. Epub 2016 Dec 21.

11.

S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization.

Lee MH, Appleton KM, El-Shewy HM, Sorci-Thomas MG, Thomas MJ, Lopes-Virella MF, Luttrell LM, Hammad SM, Klein RL.

J Lipid Res. 2017 Feb;58(2):325-338. doi: 10.1194/jlr.M070706. Epub 2016 Nov 23.

12.

CD36 is upregulated in mice with periodontitis and metabolic syndrome and involved in macrophage gene upregulation by palmitate.

Lu Z, Li Y, Brinson CW, Kirkwood KL, Lopes-Virella MF, Huang Y.

Oral Dis. 2017 Mar;23(2):210-218. doi: 10.1111/odi.12596. Epub 2017 Jan 13.

13.

Lipopolysaccharide and IL-1β coordinate a synergy on cytokine production by upregulating MyD88 expression in human gingival fibroblasts.

Brinson CW, Lu Z, Li Y, Lopes-Virella MF, Huang Y.

Mol Immunol. 2016 Nov;79:47-54. doi: 10.1016/j.molimm.2016.09.020. Epub 2016 Sep 30.

14.

F(ab')2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice.

Li Y, Lu Z, Huang Y, Lopes-Virella MF, Virella G.

Clin Immunol. 2016 Dec;173:50-56. doi: 10.1016/j.clim.2016.07.020. Epub 2016 Jul 22.

PMID:
27455858
15.

Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study.

Hammad SM, Baker NL, El Abiad JM, Spassieva SD, Pierce JS, Rembiesa B, Bielawski J, Lopes-Virella MF, Klein RL; DCCT/EDIC Group of Investigators.

Neuromolecular Med. 2017 Mar;19(1):46-56. doi: 10.1007/s12017-016-8423-9. Epub 2016 Jul 7.

16.

High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.

Lopes-Virella MF, Hunt KJ, Baker NL, Virella G; VADT Group of Investigators.

J Diabetes Complications. 2016 May-Jun;30(4):693-9. doi: 10.1016/j.jdiacomp.2016.01.012. Epub 2016 Jan 14.

PMID:
26861948
17.

Data on carotid intima-media thickness and lipoprotein subclasses in type 1 diabetes from the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC).

Basu A, Jenkins AJ, Zhang Y, Stoner JA, Klein RL, Lopes-Virella MF, Timothy Garvey W, Lyons TJ; DCCT/EDIC Research Group.

Data Brief. 2015 Nov 22;6:33-8. doi: 10.1016/j.dib.2015.11.036. eCollection 2016 Mar.

18.

Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.

Zhang Y, Jenkins AJ, Basu A, Stoner JA, Lopes-Virella MF, Klein RL; DCCT/EDIC Research Group, Lyons TJ.

J Lipid Res. 2016 Feb;57(2):310-7. doi: 10.1194/jlr.P060657. Epub 2015 Dec 9.

19.

Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.

Basu A, Jenkins AJ, Zhang Y, Stoner JA, Klein RL, Lopes-Virella MF, Garvey WT, Lyons TJ; DCCT/EDIC Research Group.

Atherosclerosis. 2016 Jan;244:93-100. doi: 10.1016/j.atherosclerosis.2015.10.106. Epub 2015 Oct 31.

20.

TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes.

Lu Z, Zhang X, Li Y, Lopes-Virella MF, Huang Y.

Immunobiology. 2015 Nov;220(11):1246-54. doi: 10.1016/j.imbio.2015.06.016. Epub 2015 Jun 30.

21.

Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort.

Hunt KJ, Baker NL, Cleary PA, Klein R, Virella G, Lopes-Virella MF; DCCT/EDIC Group of Investigators.

Diabetes Care. 2015 Jul;38(7):1281-9. doi: 10.2337/dc14-2877. Epub 2015 Apr 7.

22.

Metabolic syndrome exacerbates inflammation and bone loss in periodontitis.

Li Y, Lu Z, Zhang X, Yu H, Kirkwood KL, Lopes-Virella MF, Huang Y.

J Dent Res. 2015 Feb;94(2):362-70. doi: 10.1177/0022034514561658. Epub 2014 Dec 11.

23.

Intracranial atherosclerosis: correlation between in-vivo 3T high resolution MRI and pathology.

Turan TN, Rumboldt Z, Granholm AC, Columbo L, Welsh CT, Lopes-Virella MF, Spampinato MV, Brown TR.

Atherosclerosis. 2014 Dec;237(2):460-3. doi: 10.1016/j.atherosclerosis.2014.10.007. Epub 2014 Oct 17.

24.

The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes.

Rajab HA, Baker NL, Hunt KJ, Klein R, Cleary PA, Lachin J, Virella G, Lopes-Virella MF; DCCT/EDIC Group of Investigators.

J Diabetes Complications. 2015 Jan-Feb;29(1):108-14. doi: 10.1016/j.jdiacomp.2014.08.004. Epub 2014 Aug 20.

25.

The role of the immune system in the pathogenesis of diabetic complications.

Virella G, Lopes-Virella MF.

Front Endocrinol (Lausanne). 2014 Jul 30;5:126. doi: 10.3389/fendo.2014.00126. eCollection 2014. No abstract available.

26.

Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes.

Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Metabolism. 2014 Oct;63(10):1287-95. doi: 10.1016/j.metabol.2014.07.001. Epub 2014 Jul 9.

27.

Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study.

Basu A, Jenkins AJ, Stoner JA, Thorpe SR, Klein RL, Lopes-Virella MF, Garvey WT, Lyons TJ; DCCT/EDIC Research Group.

Atherosclerosis. 2014 Sep;236(1):188-195. doi: 10.1016/j.atherosclerosis.2014.07.001. Epub 2014 Jul 15.

28.

Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes.

Fu D, Yu JY, Wu M, Du M, Chen Y, Abdelsamie SA, Li Y, Chen J, Boulton ME, Ma JX, Lopes-Virella MF, Virella G, Lyons TJ.

J Lipid Res. 2014 May;55(5):860-9. doi: 10.1194/jlr.M045401. Epub 2014 Mar 10.

29.

Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients.

Jenkins AJ, Fu D, Azar M, Stoner JA, Kaufman DG, Zhang S, Klein RL, Lopes-Virella MF, Ma JX, Lyons TJ; VADT investigators.

J Diabetes Complications. 2014 May-Jun;28(3):353-9. doi: 10.1016/j.jdiacomp.2014.01.008. Epub 2014 Jan 17.

30.

Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323.

Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group.

Diabetes Care. 2014 May;37(5):e108-9. doi: 10.2337/dc13-2976. Epub 2014 Feb 4. No abstract available.

31.

Simvastatin inhibits LPS-induced alveolar bone loss during metabolic syndrome.

Jin J, Machado ER, Yu H, Zhang X, Lu Z, Li Y, Lopes-Virella MF, Kirkwood KL, Huang Y.

J Dent Res. 2014 Mar;93(3):294-9. doi: 10.1177/0022034513516980. Epub 2013 Dec 18.

32.

Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.

Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Atherosclerosis. 2013 Dec;231(2):315-22. doi: 10.1016/j.atherosclerosis.2013.09.027. Epub 2013 Oct 11.

33.

Simvastatin inhibits lipopolysaccharide-induced osteoclastogenesis and reduces alveolar bone loss in experimental periodontal disease.

Jin J, Zhang X, Lu Z, Li Y, Lopes-Virella MF, Yu H, Haycraft CJ, Li Q, Kirkwood KL, Huang Y.

J Periodontal Res. 2014 Aug;49(4):518-26. doi: 10.1111/jre.12132. Epub 2013 Oct 7.

34.

Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.

Lopes-Virella MF, Virella G.

J Atheroscler Thromb. 2013;20(10):743-54. Epub 2013 Aug 20. Review.

35.
36.

Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes.

Bhensdadia NM, Hunt KJ, Lopes-Virella MF, Michael Tucker J, Mataria MR, Alge JL, Neely BA, Janech MG, Arthur JM; Veterans Affairs Diabetes Trial (VADT) study group.

Kidney Int. 2013 Jun;83(6):1136-43. doi: 10.1038/ki.2013.57. Epub 2013 Mar 27.

37.

Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects.

Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group.

Diabetes Care. 2013 Aug;36(8):2317-23. doi: 10.2337/dc12-2521. Epub 2013 Mar 20.

38.

Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes.

Virella G, Colglazier J, Chassereau C, Hunt KJ, Baker NL, Lopes-Virella MF.

J Immunoassay Immunochem. 2013;34(1):61-74. doi: 10.1080/15321819.2012.683500.

PMID:
23323982
39.

Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial.

Turan TN, Lynn MJ, Nizam A, Lane B, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Benavente O, White CL, Brown WV, Caskey MF, Steiner MR, Vilardo N, Stufflebean A, Derdeyn CP, Fiorella D, Janis S, Chimowitz MI; SAMMPRIS Investigators.

Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):e51-60. No abstract available.

40.

The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.

Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T; VADT Investigators.

Atherosclerosis. 2012 Oct;224(2):526-31. doi: 10.1016/j.atherosclerosis.2012.08.006. Epub 2012 Aug 21.

41.

The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.

Virella G, Lopes-Virella MF.

Front Endocrinol (Lausanne). 2012 Jun 15;3:76. doi: 10.3389/fendo.2012.00076. eCollection 2012.

42.

Toll-like receptor 4 activation in microvascular endothelial cells triggers a robust inflammatory response and cross talk with mononuclear cells via interleukin-6.

Lu Z, Li Y, Jin J, Zhang X, Lopes-Virella MF, Huang Y.

Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1696-706. doi: 10.1161/ATVBAHA.112.251181. Epub 2012 May 17.

43.

High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.

Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G; DCCT/EDIC Study Group.

Diabetes Care. 2012 Jun;35(6):1333-40. doi: 10.2337/dc11-2040. Epub 2012 Apr 17.

44.

Different signaling mechanisms regulating IL-6 expression by LPS between gingival fibroblasts and mononuclear cells: seeking the common target.

Jin J, Sundararaj KP, Samuvel DJ, Zhang X, Li Y, Lu Z, Lopes-Virella MF, Huang Y.

Clin Immunol. 2012 May;143(2):188-99. doi: 10.1016/j.clim.2012.01.019. Epub 2012 Feb 10.

45.

Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release.

Truman JP, Al Gadban MM, Smith KJ, Jenkins RW, Mayroo N, Virella G, Lopes-Virella MF, Bielawska A, Hannun YA, Hammad SM.

Immunology. 2012 May;136(1):30-45. doi: 10.1111/j.1365-2567.2012.03552.x.

46.

Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells.

Jin J, Samuvel DJ, Zhang X, Li Y, Lu Z, Lopes-Virella MF, Huang Y.

Mol Immunol. 2011 Dec;49(3):423-32. doi: 10.1016/j.molimm.2011.08.026. Epub 2011 Oct 26.

47.

TLR4 activation and IL-6-mediated cross talk between adipocytes and mononuclear cells synergistically stimulate MMP-1 expression.

Samuvel DJ, Jin J, Sundararaj KP, Li Y, Zhang X, Lopes-Virella MF, Huang Y.

Endocrinology. 2011 Dec;152(12):4662-71. doi: 10.1210/en.2011-1026. Epub 2011 Sep 27.

48.

High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.

Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G; DCCT/EDIC Research Group.

Nephrol Dial Transplant. 2012 Apr;27(4):1416-23. doi: 10.1093/ndt/gfr454. Epub 2011 Aug 19.

49.

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y.

J Cardiovasc Pharmacol. 2011 Aug;58(2):157-66. doi: 10.1097/FJC.0b013e31821e5626.

50.

Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice.

Schuyler CA, Ta NN, Li Y, Lopes-Virella MF, Huang Y.

J Endocrinol. 2011 Jul;210(1):37-46. doi: 10.1530/JOE-10-0420. Epub 2011 Apr 8.

PMID:
21478228

Supplemental Content

Loading ...
Support Center